Regulatory Exclusivity Expiring in 2030
Drugs with Regulatory Exclusivity Expiring in 2030
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | NEREUS | tradipitant | CAPSULE;ORAL | 220152-001 | Dec 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Astrazeneca Ab | WAINUA (AUTOINJECTOR) | eplontersen sodium | SOLUTION;SUBCUTANEOUS | 217388-001 | Dec 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS | |
| Calliditas | TARPEYO | budesonide | CAPSULE, DELAYED RELEASE;ORAL | 215935-001 | Dec 15, 2021 | RX | Yes | Yes | ⤷ Start Trial | TO REDUCE THE LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE PROVIDED FOR IN THE INDICATION APPROVED ON DECEMBER 15, 2021 | |
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-001 | Dec 19, 2025 | RX | Yes | Yes | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-002 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-003 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| Cytokinetics | MYQORZO | aficamten | TABLET;ORAL | 219083-004 | Dec 19, 2025 | RX | Yes | No | ⤷ Start Trial | NEW CHEMICAL ENTITY | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |
